Comments
Dr Reddy’s Laboratories Ltd has launched Febuxostat Tablets, a therapeutic equivalent generic version of Uloric (Febuxostat) tablets approved by the US Food and Drug Administration (USFDA).
The Uloric brand and generic had US sales of approximately $108 million MAT for the most recent twelve months, ending in October 2020, according to IQVIA Health.
Dr Reddy’s Febuxostat tablets are available in 40 mg and 80 mg strengths in bottle count sizes of 30 tablets.
Gout patients with established cardiovascular (CV) disease treated with Febuxostat had a higher rate of CV death compared to those treated with allopurinol in a CV outcomes study, it warned.
Febuxostat should only be used in patients who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.